Abstract
Original language | English |
---|---|
Pages (from-to) | 1033-1041 |
Number of pages | 9 |
Journal | Int. J. Cancer |
Volume | 145 |
Issue number | 4 |
DOIs | |
Publication status | Published - 2019 |
Keywords
- adult
- aged
- Article
- Bayes theorem
- cancer risk
- cancer screening
- clinical outcome
- cohort analysis
- colposcopy
- controlled study
- Denmark
- female
- follow up
- genotype
- histopathology
- human
- human cell
- Human papillomavirus type 16
- Human papillomavirus type 18
- Human papillomavirus type 31
- Human papillomavirus type 33
- Human papillomavirus type 52
- Human papillomavirus type 58
- human tissue
- Italy
- major clinical study
- middle aged
- nonhuman
- patient referral
- priority journal
- probability
- retrospective study
- risk assessment
- uterine cervix carcinoma in situ
- Wart virus
- young adult
- adolescent
- complication
- early cancer diagnosis
- Europe
- genetics
- mass screening
- Papillomaviridae
- papillomavirus infection
- procedures
- risk
- uterine cervix tumor
- virology
- Adolescent
- Adult
- Aged
- Bayes Theorem
- Cohort Studies
- Early Detection of Cancer
- Female
- Genotype
- Humans
- Mass Screening
- Middle Aged
- Papillomavirus Infections
- Risk
- Uterine Cervical Neoplasms
- Young Adult
Fingerprint Dive into the research topics of 'Bayesian analysis of baseline risk of CIN2 and ≥CIN3 by HPV genotype in a European referral cohort: International Journal of Cancer'. Together they form a unique fingerprint.
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Bayesian analysis of baseline risk of CIN2 and ≥CIN3 by HPV genotype in a European referral cohort : International Journal of Cancer. / Bonde, J.; Bottari, F.; Parvu, V.; Pedersen, H.; Yanson, K.; Iacobone, A.D.; Kodsi, S.; Landoni, F.; Vaughan, L.; Ejegod, D.M.; Sandri, M.T.
In: Int. J. Cancer, Vol. 145, No. 4, 2019, p. 1033-1041.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Bayesian analysis of baseline risk of CIN2 and ≥CIN3 by HPV genotype in a European referral cohort
T2 - International Journal of Cancer
AU - Bonde, J.
AU - Bottari, F.
AU - Parvu, V.
AU - Pedersen, H.
AU - Yanson, K.
AU - Iacobone, A.D.
AU - Kodsi, S.
AU - Landoni, F.
AU - Vaughan, L.
AU - Ejegod, D.M.
AU - Sandri, M.T.
N1 - Cited By :3 Export Date: 26 February 2020 CODEN: IJCNA Correspondence Address: Bonde, J.; Molecular Pathology Laboratory, Department of Pathology, Copenhagen University, Hvidovre HospitalDenmark; email: jesper.hansen.bonde@regionh.dk Tradenames: Onclarity; Thin Prep 5000, Hologic, United States Manufacturers: Hologic, United States Funding details: Budget Division, BD Funding text 1: The authors are grateful for the contribution to this study by the group of gynecologists performing colposcopies, and biopsy taking, as well as to the laboratory staff in both Milan and Copenhagen assisting in registering, handling, processing and testing the samples in our study. The funding for our study was provided by BD Diagnostics, Sparks, MA, USA. The funders had the right to read and comment upon the article, but without editorial rights, nor any role in the final interpretation of the data. References: Schiffman, M., Castle, P.E., Jeronimo, J., Human papillomavirus and cervical cancer (2007) Lancet, 370, pp. 890-907; Wright, T.C., Jr., Schiffman, M., Adding a test for human papillomavirus DNA to cervical-cancer screening (2003) N Engl J Med, 348, pp. 489-490; McCredie, M.R., Sharples, K.J., Paul, C., Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study (2008) Lancet Oncol, 9, pp. 425-434; Schiffman, M., Rodriguez, A.C., Heterogeneity in CIN3 diagnosis (2008) Lancet Oncol, 9, pp. 404-406; Lynge, E., Rygaard, C., Baillet, M.V., Cervical cancer screening at crossroads (2014) APMIS, 122, pp. 667-673; Rebolj, M., Rask, J., van Ballegooijen, M., Cervical histology after routine ThinPrep or SurePath liquid-based cytology and computer-assisted reading in Denmark (2015) Br J Cancer, 113, pp. 1259-1274; Rozemeijer, K., Penning, C., Siebers, A.G., Comparing SurePath, ThinPrep, and conventional cytology as primary test method: SurePath is associated with increased CIN II+ detection rates (2016) Cancer Causes Control, 27, pp. 15-25; Koliopoulos, G., Nyaga, V.N., Santesso, N., Cytology versus HPV testing for cervical cancer screening in the general population (2017) Cochrane Database Syst Rev, 8, p. CD008587; Ronco, G., Dillner, J., Elfstrom, K.M., Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials (2014) Lancet, 383, pp. 524-532; Tota, J.E., Bentley, J., Blake, J., Introduction of molecular HPV testing as the primary technology in cervical cancer screening: acting on evidence to change the current paradigm (2017) Prev Med, 98, pp. 5-14; Schiffman, M., Vaughan, L.M., Raine-Bennett, T.R., A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results (2015) Gynecol Oncol, 138, pp. 573-578; Schiffman, M., Hyun, N., Raine-Bennett, T.R., A cohort study of cervical screening using partial HPV typing and cytology triage (2016) Int J Cancer, 139, pp. 2606-2615; Wentzensen, N., Schiffman, M., Palmer, T., Triage of HPV positive women in cervical cancer screening (2016) J Clin Virol, 76, pp. 49-55; Ejegod, D., Bottari, F., Pedersen, H., The BD Onclarity HPV assay on samples collected in SurePath medium meets the international guidelines for human papillomavirus test requirements for cervical screening (2016) J Clin Microbiol, 54, pp. 2267-2272; Ejegod, D., Serrano, I., Cuschieri, K., Clinical validation of the BD Onclarity™ HPV assay using a non-inferiority test (2013) Med Microbiol Diagn, S3, p. 003; Stoler, M.H., Wright, T.C., Jr., Parvu, V., The Onclarity human papillomavirus trial: design, methods, and baseline results (2018) Gynecol Oncol, 149, pp. 498-505; Wright, T.C., Jr., Stoler, M.H., Parvu, V., Detection of cervical Neoplasia by human papillomavirus testing in an atypical squamous cells-undetermined significance population: results of the Becton Dickinson Onclarity trial (2018) Am J Clin Pathol, 151, pp. 53-62; Bottari, F., Sideri, M., Gulmini, C., Comparison of Onclarity human papillomavirus (HPV) assay with hybrid capture II HPV DNA assay for detection of cervical intraepithelial Neoplasia grade 2 and 3 lesions (2015) J Clin Microbiol, 53, pp. 2109-2114; Ejegod, D.M., Junge, J., Franzmann, M., Clinical and analytical performance of the BD Onclarity HPV assay for detection of CIN2+ lesions on SurePath samples (2016) Papillomavirus Res, 2, pp. 31-37; Goldman, B., Rebolj, M., Rygaard, C., Patterns of cervical coinfection with multiple human papilloma virus types in a screening population in Denmark (2013) Vaccine, 31, pp. 1604-1609; Wentzensen, N., Wilson, L.E., Wheeler, C.M., Hierarchical clustering of human papilloma virus genotype patterns in the ASCUS-LSIL triage study (2010) Cancer Res, 70, pp. 8578-8586; Schiffman, M., Burk, R.D., Boyle, S., A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results (2015) J Clin Microbiol, 53, pp. 52-59; Smelov, V., Elfstrom, K.M., Johansson, A.L., Long-term HPV type-specific risks of high-grade cervical intraepithelial lesions: a 14-year follow-up of a randomized primary HPV screening trial (2015) Int J Cancer, 136, pp. 1171-1180; Mirabello, L., Yeager, M., Yu, K., HPV16 E7 genetic conservation is critical to carcinogenesis (2017) Cell, 170, pp. 1164-74 e6; Cuschieri, K., Ronco, G., Lorincz, A., Eurogin roadmap 2017: triage strategies for the management of HPV-positive women in cervical screening programs (2018) Int J Cancer, 143, pp. 735-745; Stanczuk, G.A., Baxter, G.J., Currie, H., Defining optimal triage strategies for hrHPV screen-positive women—an evaluation of HPV 16/18 genotyping, cytology, and p16/Ki-67 cytoimmunochemistry (2017) Cancer Epidemiol Biomarkers Prev, 26, pp. 1629-1635; Tota, J.E., Bentley, J., Blake, J., Approaches for triaging women who test positive for human papillomavirus in cervical cancer screening (2017) Prev Med, 98, pp. 15-20; Massad, L.S., Einstein, M.H., Huh, W.K., 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors (2013) J Low Genit Tract Dis, 17, pp. 1-S27; Cuzick, J., Ho, L., Terry, G., Individual detection of 14 high risk human papilloma virus genotypes by the PapType test for the prediction of high grade cervical lesions (2014) J Clin Virol, 60, pp. 44-49; Thomsen, L.T., Frederiksen, K., Munk, C., Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology (2015) Int J Cancer, 137, pp. 193-203; Castle, P.E., Shaber, R., LaMere, B.J., Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente northern California (2011) Cancer Epidemiol Biomarkers Prev, 20, pp. 946-953; Clifford, G.M., Smith, J.S., Plummer, M., Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis (2003) Br J Cancer, 88, pp. 63-73; Wheeler, C.M., Hunt, W.C., Cuzick, J., The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: a population-based study of opportunistic cervical screening in the United States (2014) Int J Cancer, 135, pp. 624-634; Cuzick, J., Myers, O., Lee, J.H., Outcomes in women with cytology showing atypical squamous cells of undetermined significance with vs without human papillomavirus testing (2017) JAMA Oncol, 3, pp. 1327-1334; Gage, J.C., Hunt, W.C., Schiffman, M., Risk stratification using human papillomavirus testing among women with equivocally abnormal cytology: results from a state-wide surveillance program (2016) Cancer Epidemiol Biomarkers Prev, 25, pp. 36-42; Rebolj, M., Lynge, E., Ejegod, D., Comparison of three human papillomavirus DNA assays and one mRNA assay in women with abnormal cytology (2014) Gynecol Oncol, 135, pp. 474-480; Cuzick, J., Wheeler, C., Need for expanded HPV genotyping for cervical screening (2016) Papillomavirus Res, 2, pp. 112-115; Gage, J.C., Hunt, W.C., Schiffman, M., Similar risk patterns after cervical screening in two large U.S. populations: implications for clinical guidelines (2016) Obstet Gynecol, 128, pp. 1248-1257; Chen, H.C., Schiffman, M., Lin, C.Y., Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer (2011) J Natl Cancer Inst, 103, pp. 1387-1396; Elfgren, K., Elfstrom, K.M., Naucler, P., Management of women with human papillomavirus persistence: long-term follow-up of a randomized clinical trial (2017) Am J Obstet Gynecol, 216, pp. 264 e1-7; Sundstrom, K., Eloranta, S., Sparen, P., Prospective study of human papillomavirus (HPV) types, HPV persistence, and risk of squamous cell carcinoma of the cervix (2010) Cancer Epidemiol Biomarkers Prev, 19, pp. 2469-2478; Arbyn, M., Depuydt, C., Benoy, I., VALGENT: a protocol for clinical validation of human papillomavirus assays (2016) J Clin Virol, 76, pp. 14-21; Arbyn, M., Snijders, P.J., Meijer, C.J., Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? (2015) Clin Microbiol Infect, 21, pp. 817-826; Hestbech, M.S., Lynge, E., Kragstrup, J., The impact of HPV vaccination on future cervical screening: a simulation study of two birth cohorts in Denmark (2015) BMJ Open, 5; Lew, J.B., Simms, K.T., Smith, M.A., Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program (2017) Lancet Public Health, 2, pp. e96-e107; Massad, L.S., Anticipating the impact of human papillomavirus vaccination on US cervical cancer prevention strategies (2018) J Low Genit Tract Dis, 22, pp. 123-125; Oliver, S.E., Unger, E.R., Lewis, R., Prevalence of human papillomavirus among females after vaccine Introduction-National Health and nutrition examination survey, United States, 2003-2014 (2017) J Infect Dis, 216, pp. 594-603; Pedersen, K., Burger, E.A., Nygard, M., Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: the value of stratifying guidelines (2018) Eur J Cancer, 91, pp. 68-75
PY - 2019
Y1 - 2019
N2 - Whereas HPV16 and HPV18 have been the focus in current risk-based cervical cancer screening algorithms using HPV genotype information, mounting evidence suggests that oncogenic HPV types such as HPV31, 33, 52 and 58 pose a ≥CIN3 risk equivalent to or greater than that of HPV18, and the combined risk of HPV31 and HPV33 rivals even HPV16 in women above 30 years of age. Here, we evaluate the baseline risk of CIN2 and CIN3 by genotype in a colposcopy referral population from Denmark and Italy. In total, 655 women were enrolled upon a referral to colposcopy after a positive screening sample. All samples were HPV analyzed using Onclarity HPV assay with extended genotyping and combined with the histology outcomes, a Bayesian probability modeling was used to determine the risk per genotype assessed. The combined data for this referral population showed that the ≥CIN2 risk of HPV16 was 69.1%, HPV31 at 63.3%, HPV33/58 at 52.7%, HPV18 at 46.6% and HPV52 at 40.8%. For ≥CIN3, the risks were 44.3%, 38.5%, 36.8%, 30.9% and 16.8% for HPV16, HPV31, HPV18, HPV33/58 and HPV52, respectively, indicating that the baseline risk of disease arising from HPV16 is, not surprisingly, the highest among the oncogenic HPV genotypes. We find that the HPV genotype-specific ≥CIN2 and ≥CIN3 risk-patterns are so distinct that, for example, 35/39/68 and 56/59/66 should be considered only for low intensive follow-up, thereby proposing active use of this information in triage strategies for screening HPV-positive women. © 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC
AB - Whereas HPV16 and HPV18 have been the focus in current risk-based cervical cancer screening algorithms using HPV genotype information, mounting evidence suggests that oncogenic HPV types such as HPV31, 33, 52 and 58 pose a ≥CIN3 risk equivalent to or greater than that of HPV18, and the combined risk of HPV31 and HPV33 rivals even HPV16 in women above 30 years of age. Here, we evaluate the baseline risk of CIN2 and CIN3 by genotype in a colposcopy referral population from Denmark and Italy. In total, 655 women were enrolled upon a referral to colposcopy after a positive screening sample. All samples were HPV analyzed using Onclarity HPV assay with extended genotyping and combined with the histology outcomes, a Bayesian probability modeling was used to determine the risk per genotype assessed. The combined data for this referral population showed that the ≥CIN2 risk of HPV16 was 69.1%, HPV31 at 63.3%, HPV33/58 at 52.7%, HPV18 at 46.6% and HPV52 at 40.8%. For ≥CIN3, the risks were 44.3%, 38.5%, 36.8%, 30.9% and 16.8% for HPV16, HPV31, HPV18, HPV33/58 and HPV52, respectively, indicating that the baseline risk of disease arising from HPV16 is, not surprisingly, the highest among the oncogenic HPV genotypes. We find that the HPV genotype-specific ≥CIN2 and ≥CIN3 risk-patterns are so distinct that, for example, 35/39/68 and 56/59/66 should be considered only for low intensive follow-up, thereby proposing active use of this information in triage strategies for screening HPV-positive women. © 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC
KW - adult
KW - aged
KW - Article
KW - Bayes theorem
KW - cancer risk
KW - cancer screening
KW - clinical outcome
KW - cohort analysis
KW - colposcopy
KW - controlled study
KW - Denmark
KW - female
KW - follow up
KW - genotype
KW - histopathology
KW - human
KW - human cell
KW - Human papillomavirus type 16
KW - Human papillomavirus type 18
KW - Human papillomavirus type 31
KW - Human papillomavirus type 33
KW - Human papillomavirus type 52
KW - Human papillomavirus type 58
KW - human tissue
KW - Italy
KW - major clinical study
KW - middle aged
KW - nonhuman
KW - patient referral
KW - priority journal
KW - probability
KW - retrospective study
KW - risk assessment
KW - uterine cervix carcinoma in situ
KW - Wart virus
KW - young adult
KW - adolescent
KW - complication
KW - early cancer diagnosis
KW - Europe
KW - genetics
KW - mass screening
KW - Papillomaviridae
KW - papillomavirus infection
KW - procedures
KW - risk
KW - uterine cervix tumor
KW - virology
KW - Adolescent
KW - Adult
KW - Aged
KW - Bayes Theorem
KW - Cohort Studies
KW - Early Detection of Cancer
KW - Female
KW - Genotype
KW - Humans
KW - Mass Screening
KW - Middle Aged
KW - Papillomavirus Infections
KW - Risk
KW - Uterine Cervical Neoplasms
KW - Young Adult
U2 - 10.1002/ijc.32291
DO - 10.1002/ijc.32291
M3 - Article
VL - 145
SP - 1033
EP - 1041
JO - Int. J. Cancer
JF - Int. J. Cancer
SN - 0020-7136
IS - 4
ER -